Canada Spends Logo

Explore our Budget 2026 analysis

Grant: Master's Award: Canada Graduate Scholarships

McMaster University

$17,500.00

Imaging Biomarkers to Characterize Emphysema Progression: Evidence and Endpoints for the Development of Matrix Metalloproteinase-12 Inhibitors

FY 2021-22

Summary
Chronic obstructive pulmonary disease (COPD) affects our lungs and is a leading cause of hospital admission and death in Canada. COPD is caused by chronic exposure to toxic air pollutants and cigarette smoke, that lead to the release of inflammatory chemical signals and damage to the air sacs (alveoli) in the lungs, this is known as emphysema. Currently available treatments for COPD only relieve symptoms and are not disease modifying. Scientists have identified matrix metalloproteinase-12 (MMP12) to promote emphysema by acting as ;molecular shredders to tear apart alveolis structural ability to transfer oxygen into the blood. But scientists still do not know how MMP12 influences the progression of emphysema. Recent advances in high-resolution lung magnetic resonance imaging (MRI) and computed tomography (CT) can now visualize and measure COPD progression. Many COPD patients will eventually develop emphysema thus investigating MMP12s involvement in disease progression is important to guide the development of new therapies targeting MMP12. The proposed research combines clinical and medical imaging approaches to understand the role of MMP12 in emphysema progression. Our team of scientists think COPD patients with emphysema will have high MMP12 levels and the amount of MMP12 in airway secretion and/or blood are associated with progressive alveolar destruction measured by MRI and CT. We will study 60 COPD patients with emphysema and 15 healthy volunteers by examining their airway secretions, blood, and lung imaging scans. The proposed study will determine the best imaging tool to evaluate emphysema progression and the role of MMP12 in this process. This will set the stage for new treatments to help reduce the huge burden of COPD for over two million Canadians.
Program
Master's Award: Canada Graduate Scholarships
Location
Ontario, Canada
Recipient Type
Academia
Type
Grant
Source
CIHR Funding Decisions Database

As published

Id
466577
Name
Thakar Ashutosh
Region
Ontario
Country
Canada
Orgtype
Institution Paid; Research Institution
Prcname2
Special Cases - Awards Programs
Projecttitle
Imaging Biomarkers to Characterize Emphysema Progression: Evidence and Endpoints for the Development of Matrix Metalloproteinase-12 Inhibitors
Programtype2
Studentship Programs
Orgnameinp2
McMaster University
Cihramount2
$17,500
Cihrequipment2
$0
Programname2
Master's Award: Canada Graduate Scholarships
Keyworddelim
Chronic Obstructive Pulmonary Disease (Copd); Computed Tomography; Cytokines And Chemokines; Disease Progression; Emphysema; Hyperpolarized Magnetic Resonance Imaging; Imaging Biomarkers Of Copd; Lung Inflammation; Matrix Metalloproteinase-12; Sputum And Blood
Abstract
Chronic obstructive pulmonary disease (COPD) affects our lungs and is a leading cause of hospital admission and death in Canada. COPD is caused by chronic exposure to toxic air pollutants and cigarette smoke, that lead to the release of inflammatory chemical signals and damage to the air sacs (alveoli) in the lungs, this is known as emphysema. Currently available treatments for COPD only relieve symptoms and are not disease modifying. Scientists have identified matrix metalloproteinase-12 (MMP12) to promote emphysema by acting as ;molecular shredders to tear apart alveolis structural ability to transfer oxygen into the blood. But scientists still do not know how MMP12 influences the progression of emphysema. Recent advances in high-resolution lung magnetic resonance imaging (MRI) and computed tomography (CT) can now visualize and measure COPD progression. Many COPD patients will eventually develop emphysema thus investigating MMP12s involvement in disease progression is important to guide the development of new therapies targeting MMP12. The proposed research combines clinical and medical imaging approaches to understand the role of MMP12 in emphysema progression. Our team of scientists think COPD patients with emphysema will have high MMP12 levels and the amount of MMP12 in airway secretion and/or blood are associated with progressive alveolar destruction measured by MRI and CT. We will study 60 COPD patients with emphysema and 15 healthy volunteers by examining their airway secretions, blood, and lung imaging scans. The proposed study will determine the best imaging tool to evaluate emphysema progression and the role of MMP12 in this process. This will set the stage for new treatments to help reduce the huge burden of COPD for over two million Canadians.
Competitiondate
202112
Approvedterm2
1 yr 0 mth
Pinamesdelim
Thakar, Ashutosh
Approvedterm
1 an 0 mois
Cihrcontribution2
~ $17,500~ $0~